Journal of Clinical Oncology
Articles in this Issue
Enhancing early detection of lung cancer: Methylation anchor probe for low-signal enrichment (MAPLE).
8057 Background: Non-Small Cell Lung Cancer (NSCLC) is among the most lethal cancers worldwide. Lung adenocarcinoma (LUAD) and lung squamous cell carcinom...
Final analysis of a multicenter, open-label, phase 2 study evaluating the efficacy and safety of tislelizumab (TIS) in combination with fruquintinib (F) in patients (pts) with selected solid tumors.
2604 Background: Immunotherapy in combination with antiangiogenic agents has shown promising antitumor activity compared with either agent alone. We repor...
Preliminary monotherapy efficacy of novel immune checkpoint blockade GV20-0251 (anti-IGSF8) in advanced melanoma patients with primary resistance to anti-PD1.
2531 Background: GV20-0251 is an AI-designed, first-in-class, cross-species reactive, Fc-attenuated IgG1 antibody that targets the novel cancer immune che...
Radiomic analysis on pretreatment MRI to predict response to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma: A multicenter study.
4104 Background: The combination of atezolizumab and bevacizumab is the standard treatment for advanced hepatocellular carcinoma approved in China and man...
Intermittent fasting (IF) during PD-1 checkpoint blockade: A pilot safety and feasibility study.
e23008 Background: Dysregulated metabolism, including increased glycolysis and production of immunosuppressive metabolites, may contribute to immune escap...
Population-adjusted indirect comparison (PAIC) of avelumab (AVE) and retifanlimab (RETI) in the first-line (1L) treatment of patients (pts) with metastatic Merkel cell carcinoma (mMCC).
e21513 Background: In 2017, AVE was the first immunotherapy (IO) to receive regulatory approval for mMCC. The IO agent RETI has also since been approved....
A systematic review and critical appraisal of current recommendations for lung cancer screening.
e20124 Background: Strengthening the screening of Lung Cancer in Europe (SOLACE) is an initiative funded by the European Union (EU) under the EU4Health Fr...
Comparing outcomes of lymphoma-directed CAR T-cell therapy in patients with and without HIV: A retrospective cohort study from a global health research network.
7034 Background: Since its introduction into the world of oncology, chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of rel...
Utilization and impact of a digital care platform on cancer patients in India.
1576 Background: Cancer patients experience complex symptoms and treatment-related side effects that impair quality of life (QoL) and increase healthcare...
Neoadjuvant camrelizumab plus apatinib and temozolomide for resectable stage II/III acral melanoma: The CAP 03-NEO trial.
9512 Background: The CAP 03 study demonstrated significant efficacy for camrelizumab combined with apatinib and temozolomide as first-line therapy for adv...
Subgroup analysis of efficacy and safety of fruquintinib plus paclitaxel versus paclitaxel in gastroesophageal junction adenocarcinoma patients from FRUTIGA: A randomized phase 3 clinical trial in second-line treatment of gastric/gastroesophageal junction adenocarcinoma.
e16012 Background: It has been previously reported that fruquintinib (F)+ paclitaxel (PTX) significantly improved progression-free survival (PFS), objecti...
General practitioner-led vs surgeon-led colon cancer survivorship care: A randomized clinical trial.
1513 Background: The role of general practitioners (GPs) in providing survivorship care for cancer patients remains debated. In 2015, the randomized I CAR...
Perceptions of Vietnamese women regarding HPV self-collection: A cross-sectional analysis.
e17530 Background: Cervical cancer remains a significant public health challenge, especially in low-resource settings such as Vietnam. HPV self-collection...
Prognostic impact of ER staining patterns and heterogeneity of ER-positive HER2-negative breast cancer.
e12535 Background: Estrogen receptor (ER) expression is critical in breast cancer treatment. While low ER (1%-9%) resembles triple-negative cancer with ch...
Impact of Medicare Advantage (MA) on timely initiation of pembrolizumab among dMMR/MSI-h metastatic colorectal cancer patients.
3548 Background: With MA plans covering over half of Medicare beneficiaries, concerns remain about their ability to manage complex cancer care due to pre-...
Trends in small cell lung cancer incidence and projections of future burden through 2050.
e20119 Background: Limited studies have explored the population-level incidence of small cell lung cancer (SCLC) in the United States. Given recent demogr...
ctDNA-based MRD detection in unresectable NSCLC undergoing curatively intended chemoradiotherapy and durvalumab.
8011 Background: Durvalumab consolidation after chemoradiotherapy (CRT) has improved clinical outcomes in patients with unresectable stage III non-small c...
Updated results of anlotinib plus benmelstobart combined with nab-paclitaxel and cisplatin as first-line treatment for advanced biliary tract cancer: A single-arm, open-label phase II clinical trial.
e16224 Background: Efficacy and prognosis of chemotherapy in first-line setting for patients with advanced biliary tract cancer (BTC) was dismal currently...
Efficacy and safety outcomes of obecabtagene autoleucel (obe-cel) stratified by age in patients (pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).
6576 Background: CD19 chimeric antigen receptor T-cell therapy (CAR T) exhibits good efficacy in adults with R/R B-ALL but is associated with higher toxic...
Host immune classifier to predict survival with chemoimmunotherapy in PD-L1 ≥50% metastatic NSCLC.
8533 Background: In the 1st line treatment of advanced NSCLC with PD-L ≥50%, immune checkpoint inhibitor (ICI) monotherapy and chemoimmunotherapy have dem...
Muscle mass evaluation among ambulatory cancer patients in China: Comparison of different methods and association with survival.
12080 Background: Cancer patients are at high risk of malnutrition and cachexia. Muscle mass reduction (MMR) is one of the three phenotypic criteria to di...
Shorespan-007: Phase 3 study of bomedemstat versus hydroxyurea in essential thrombocythemia naive to cytoreductive therapy.
TPS6587 Background: Lysine-specific demethylase 1 (LSD1) is an enzyme that regulates hematopoietic stem and progenitor cell proliferation and maturation....
Exploring the weekend effect and other predictors of mortality in tumor lysis syndrome among hospitalized adults.
e23137 Background: Tumor lysis syndrome (TLS) is an oncologic emergency characterized by rapid cell lysis and metabolic disturbances leading to potentiall...
Comparision of operative outcomes based on exposure to neoadjuvant chemotherapy in minimally invasive surgery for rectal cancer.
e15639 Background: Neoadjuvant Chemotherapy (NACT) followed by resection of tumor through surgery is the current standard of care for locally advanced rec...
Potential benefits of using a different donor for transplantation consolidation after donor-derived CD7 CAR T.
6536 Background: Stem cell transplantation (SCT) is often used in patients with relapsed or refractory T-cell acute lymphoblastic leukemia (r/r T-ALL) aft...